A multicenter retrospective study comparing outcome between Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax as upfront treatment for newly diagnosed AML

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Venetoclax (Primary) ; Antineoplastics
Indications Acute myeloid leukaemia
Focus Therapeutic Use

13 Dec 2022 Results (n=147) assessing the post-transplant outcomes of patients who were treated with HMA+Ven compared to CPX-351 along with the factors that help choose between IC and HMA+Ven for fit patients that are transplant candidates, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
27 Jan 2022 New trial record
14 Dec 2021 The study will be further expanded to include additional centers as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com